Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368089 | 0.80 | CYP3A4 (0.30) | SMYD2 | |
| SCHEMBL31431189 | 0.74 | ADRA1D (0.35) | ABL1SMYD2 | |
| SCHEMBL19475198 | 0.73 | PTGES2 (0.38) | CA1CA2CA4SMYD2CA12 | |
| SCHEMBL1179211 | 0.73 | CA2 (0.49) | CA1CA2CA4CA6CA12 | |
| SCHEMBL6260193 | 0.72 | SMYD2 (0.35) | SMYD2 | |
| SCHEMBL23461611 | 0.69 | SMYD2 (0.38) | CA1CA2CA4CA6SMYD2 | |
| SCHEMBL5561672 | 0.69 | IDO1 (0.41) | ABL1SMYD2 | |
| SCHEMBL22774158 | 0.69 | SMYD2 (0.32) | ABL1SMYD2 | |
| SCHEMBL1244136 | 0.69 | SLC6A4 (0.37) | ABL1SMYD2 | |
| SCHEMBL8188654 | 0.69 | L3MBTL1 (0.37) | SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | CA1 162/4885CA2 319/4885CA4 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.